×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HALO – halozyme therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HALO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/23
05:31 am
halo
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]
Low
Report
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]
12/23
03:32 am
halo
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
Low
Report
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
12/23
12:27 am
halo
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
Low
Report
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
12/22
09:34 am
halo
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]
Low
Report
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]
12/19
08:04 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
12/18
07:00 am
halo
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
Medium
Report
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
12/15
04:07 am
halo
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) [Seeking Alpha]
Low
Report
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) [Seeking Alpha]
12/8
04:05 pm
halo
Jim Lang Elected to Halozyme's Board of Directors
Low
Report
Jim Lang Elected to Halozyme's Board of Directors
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
2.8%
halozyme therapeutics, inc.
8/5/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
2.4%
halozyme therapeutics, inc.
5/6/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
18.1%
halozyme therapeutics, inc.
2/18/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
-0.2%
halozyme therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
05:40 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Nov 01 Filed by: Caudill Cortney
Low
Report
Form 4 HALOZYME THERAPEUTICS, For: Nov 01 Filed by: Caudill Cortney
12/11
06:16 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Dec 09 Filed by: Torley Helen
Low
Report
Form 4 HALOZYME THERAPEUTICS, For: Dec 09 Filed by: Torley Helen
12/9
04:45 pm
halo
Form 8-K HALOZYME THERAPEUTICS, For: Dec 04
Low
Report
Form 8-K HALOZYME THERAPEUTICS, For: Dec 04
12/8
05:20 pm
halo
Form 8-K HALOZYME THERAPEUTICS, For: Dec 04
Low
Report
Form 8-K HALOZYME THERAPEUTICS, For: Dec 04
12/1
07:51 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Dec 01 Filed by: Connaughton Bernadette
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Dec 01 Filed by: Connaughton Bernadette
12/1
07:32 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Nov 26 Filed by: Torley Helen
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Nov 26 Filed by: Torley Helen
11/24
04:07 pm
halo
Form 8-K HALOZYME THERAPEUTICS, For: Nov 18
Low
Report
Form 8-K HALOZYME THERAPEUTICS, For: Nov 18
11/18
04:50 pm
halo
Form S-8 HALOZYME THERAPEUTICS,
Low
Report
Form S-8 HALOZYME THERAPEUTICS,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/12
Form 8-K/A HALOZYME THERAPEUTICS, For: Oct 30
21.4%
11/5 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $16.00 price target on the stock, down previously from $17.00. 10.6%
5/1 FDA OKs subcutaneous version of J&J's Darzalex [Seeking Alpha] 8.1%
3/20 Form DEFA14A HALOZYME THERAPEUTICS, 8.0%
1/9 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. 8.0%
4/3 Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Sun Elaine D 6.2%
1/14 Halozyme Provides 2020 Business Update And Financial Guidance 5.9%
1/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 5.4%
3/19 Form 4 HALOZYME THERAPEUTICS, For: Mar 19 Filed by: Kelley Kenneth J 4.5%
11/13 Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 4.5%
11/5 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $16.00 price target on the stock, down previously from $17.00. 10.6%
5/1 FDA OKs subcutaneous version of J&J's Darzalex [Seeking Alpha] 8.1%
3/20 Form DEFA14A HALOZYME THERAPEUTICS, 8.0%
1/9 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. 8.0%
4/3 Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Sun Elaine D 6.2%
1/14 Halozyme Provides 2020 Business Update And Financial Guidance 5.9%
1/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 5.4%
3/19 Form 4 HALOZYME THERAPEUTICS, For: Mar 19 Filed by: Kelley Kenneth J 4.5%
11/13 Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 4.5%
TOP News Decliners
2/27
argenx SE (ARGX) Q4 2019 Earnings Call Transcript [The Motley Fool]
-4.5%
4/3 Halozyme Announces Change Of Location Of Annual Stockholders' Meeting -4.4%
2/26 Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference -4.3%
5/13 Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 -4.2%
8/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.9%
8/6 Halozyme Reports Second Quarter 2019 Results -3.2%
9/4 Form 8-K HALOZYME THERAPEUTICS, For: Sep 04 -3.2%
2/25 Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JPMorgan Chase & Co. from $24.00 to $22.00. They now have an "overweight" rating on the stock. -3.0%
7/19 Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology -3.0%
7/3 Form SC 13D/A HALOZYME THERAPEUTICS Filed by: KIRK RANDAL J -2.0%
4/3 Halozyme Announces Change Of Location Of Annual Stockholders' Meeting -4.4%
2/26 Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference -4.3%
5/13 Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 -4.2%
8/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.9%
8/6 Halozyme Reports Second Quarter 2019 Results -3.2%
9/4 Form 8-K HALOZYME THERAPEUTICS, For: Sep 04 -3.2%
2/25 Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JPMorgan Chase & Co. from $24.00 to $22.00. They now have an "overweight" rating on the stock. -3.0%
7/19 Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology -3.0%
7/3 Form SC 13D/A HALOZYME THERAPEUTICS Filed by: KIRK RANDAL J -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: